FDA Approved: REYVOW — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

The FDA approved a supplemental application for REYVOW (lasmiditan) submitted by Eli Lilly and Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• REYVOW (Lasmiditan)

Snippet

SUPPL AP for REYVOW (LASMIDITAN)